Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 83, Issue 2, 2009, Pages 233-240

  Kikuchi, Masatoshi ^a   Abe, Nobuyuki ^b   Kato, Mitsutoshi ^c   Terao, Shinji ^d   Mimori, Nobuyuki ^d   Tachibana, Hideo ^d  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b Abe Diabetes Clinic   (Japan)

^c Kato Ladies Clinic   (Japan)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

HbA1c; Japanese; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; VILDAGLIPTIN;

ADULT; AGED; ALLERGY; ARTICLE; B LYMPHOCYTE; BEDTIME DOSAGE; BODY WEIGHT; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; INFLUENZA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEASONAL ALLERGY; SIDE EFFECT; STOMACH CANCER; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; NITRILES; PLACEBOS; PYRROLIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58349115426     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.10.006     Document Type: Article

References (29)

1. Porte D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diab. Metab. Res. Rev. 17 (2001) 181-188
2. Hussain A., Claussen B., Ramachandran A., and Williams R. Prevention of type 2 diabetes: a review. Diab. Res. Clin. Pract. 76 (2007) 317-326
3. Matsuoka K. Genetic and environmental interaction in Japanese type 2 diabetics. Diab. Res. Clin. Pract. 50 Suppl. 2 (2000) S17-S22
4. Nakanishi S., Okubo M., Yoneda M., Jitsuiki K., Yamane K., and Kohno N. Comparison between Japanese-Americans living in Hawaii and Los Angeles and native Japanese: the impact of lifestyle westernization on diabetes mellitus. Biomed. Pharmacother. 58 (2004) 571-577
5. Hirose T., and Kawamori R. Diabetes in Japan. Curr. Diab. Rep. 5 (2005) 226-229
6. Kawamori R. Diabetes trends in Japan. Diab. Metab. Res. Rev. 18 (2002) S9-S13
7. Kanauchi M., Nakajima M., Saito Y., and Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism 52 4 (2003) 476-481
8. Fukushima M., Usami M., Ikeda M., Nakai Y., Taniguchi A., Suzuki H., et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 53 (2004) 831-835
9. Giorgino F., Laviola L., Leonardini A., and Natalicchio A. GLP-1: a new approach for type 2 diabetes therapy. Diab. Res. Clin. Pract. 74 (2006) S152-S155
10. Brubaker P.L., and Drucker D.J. Mini review: glucagon-like peptides regulates cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145 (2004) 2653-2659
11. Ahrén B., Landin-Olsson M., Jansson P.-A., Svenson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagons levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 2078-2084
12. Mari A., Scherbaum W.A., Nilsson P.M., Lalanne G., Schweizer A., Dunning B.E., et al. Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia. J. Clin. Endocrinol. Metab. 93 (2008) 103-109
13. Pi-Sunyer F.X., Schweizer A., Mills D., and Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diab. Res. Clin. Pract. 76 (2007) 132-138
14. Rosenstock J., Baron M.A., Dejager S., Mills D., and Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diab. Care 30 (2007) 217-223
15. Bosi E., Camisasca R.P., Collober C., Rochotte E., and Garber A.J. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diab. Care 30 (2007) 890-895
16. Garber A.J., Schweizer A., Baron M.A., Rochotte E., and Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diab. Obes. Metab. 9 (2007) 166-174
17. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., and Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 (2007) 1148-1155
18. The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus, Kuzuya T., Nakagawa S., Satoh J., Kanazawa Y., Iwamoto Y., Kobayashi M., et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res. Clin. Pract. 55 (2002) 65-85
19. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 7 (1985) 412-419
20. Shima K., Endo J., Oimomi M., Oshima I., Omori Y., Katayama Y., et al. Inter laboratory difference in GHb measurement in Japan-the fourth report of the GHb Standardization Committee, the Japan Diabetes Society. J. Jpn. Diab. Soc. 40 (1997) 321-326 (in Japanese)
21. Dejager S., Razac S., Foley J.E., and Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39 (2007) 218-223
22. Defronzo R.A., Ferrannini E., and Simonson D.C. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38 (1989) 387-395
23. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diab. Care 26 (2003) 881-885
24. Dejager S., Lebeaut A., Couturier A., and Schweizer A. Sustained reduction in A1C during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 55 Suppl. 1 (2006) A29
25. Hayashi N., Karube M., Kumagai Y., Fujita Y., Irie S., Ikeda Y., et al. Pharmacokinetics and pharmacodynamics of the DPP-IV inhibitor, vildagliptin, in Japanese patients with type 2 diabetes. Clin. Pharm. Ther. 81 Suppl. 1 (2007) S68 (Abstract PII-60)
26. He Y.L., Wang Y., Bullock J.M., Deacon C.F., Holst J.J., Dunning B.E., et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J. Clin. Pharmacol. 47 (2007) 633-641
27. Ristic S., Byiers S., Foley J., and Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diab. Obes. Metab. 7 (2005) 692-698
28. Kreymann B., Williams G., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1-7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
29. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87 (2002) 1239-1246